Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA).
STK-002 is an investigational medicine for the treatment of Autosomal Dominant Optic Atrophy (ADOA).
ADOA is a rare genetic disease that causes progressive and irreversible vision loss in both eyes starting in the first decade of life. Approximately 80 percent of people with ADOA are symptomatic by age 10, and approximately half are expected to become legally blind. There are currently no approved treatments for ADOA.
To read the full press release, please click here.
To read more about the study, please click here.